Growth Metrics

Pacira BioSciences (PCRX) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to -$99.6 million.

  • Pacira BioSciences' Income towards Parent Company rose 103.79% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 123.63%. This contributed to the annual value of -$99.6 million for FY2024, which is 337.30% down from last year.
  • Latest data reveals that Pacira BioSciences reported Income towards Parent Company of -$99.6 million as of FY2024, which was down 337.30% from $42.0 million recorded in FY2023.
  • Pacira BioSciences' 5-year Income towards Parent Company high stood at $145.5 million for FY2020, and its period low was -$99.6 million during FY2024.
  • Over the past 3 years, Pacira BioSciences' median Income towards Parent Company value was $15.9 million (recorded in 2022), while the average stood at -$13.9 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first spiked by 1,421.01% in 2020, then tumbled by 337.30% in 2024.
  • Pacira BioSciences' Income towards Parent Company (Yearly) stood at $145.5 million in 2020, then slumped by 71.15% to $42.0 million in 2021, then plummeted by 62.10% to $15.9 million in 2022, then soared by 163.72% to $42.0 million in 2023, then tumbled by 337.30% to -$99.6 million in 2024.